Navigation Links
Amarantus BioSciences Announces MANF Demonstrates Superiority over GDNF in Neurorestoration Behavioural Animal Model of Parkinson's Disease
Date:10/25/2012

nigra, and creating Parkinson's-like behavioural symptoms that were quantified by counting the number of times the rats turned in a circle in the same direction (behavioural deficits) in a given 120 minute period of time. MANF and GDNF were delivered directly into the substantia nigra of separate groups of rats 2 weeks following the administration of the 6-OHDA, in order to mimic as closely as possible in rats the treatment setting in humans where treatment would be administered after an extended timeframe following the initiation of dopaminergic nerve terminal retraction, each at the optimal dosing level of 10 micrograms. Four weeks following MANF treatment into the substantia nigra, behavioural deficits were reduced by ~43%, and six weeks following MANF treatment, behavioural deficits were reduced by ~53%; four weeks following GDNF treatment into the substantia nigra, behavioural deficits were reduced by ~16%, and six weeks following GDNF treatment, behavioural deficits actually increased by ~20%. 

"The data obtained in this study provide clear evidence that MANF had a strong positive and restorative effect on the behaviour of animals in this pre-clinical Parkinson's disease study when delivered to the substantia nigra, whereas GDNF had no such effect," said John W. Commissiong PhD, Chief Scientist at Amarantus and former Head of the Neurotrophic Factors Group at the National Institutes of Health. "The localization of the drug treatment in this study is critical because, as Parkinson's disease progresses, dopaminergic nerve terminals typically retract from the striatum towards their cell bodies in the substantia nigra, resulting in the disruption of the basal ganglia network that is responsible for proper motor function. Translated, the longer you have Parkinson's disease, the less likely a neurotrophic factor will work when delivered to the striatum because there are fewer dopaminergic nerve terminals remaining to act on, and so neurotrophic factor d
'/>"/>

SOURCE Amarantus BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
2. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
4. Neurocrine Biosciences Reports First Quarter 2012 Results
5. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
8. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
9. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
10. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
11. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)...  In today,s ever-changing marketplace, call centers must meet ... connected, and increasingly impatient with slow service. The need ... and tools is driving call centers to explore new ... According to research by benchmarking firm, Best Practices, LLC, ... a call center study realize the impact of social ...
(Date:7/31/2015)... July 31, 2015 The Physician-Patient Alliance ... on July 28, 2015, "Surviving Your Hospital Stay: ... for Patient Safety." A sentence was ... read: "PPAHS is a member of ... Opioids. For more information on the National Coalition to ...
(Date:7/31/2015)... , July 31, 2015 Egalet Corporation ... specialty pharmaceutical company focused on developing, manufacturing and ... of its previously announced underwritten public offering of ... public offering price of $11.25 per share. The ... 1,000,000 shares issued upon the exercise in full ...
Breaking Medicine Technology:Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4
... March 26 Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ... agreement with W. C. Heraeus GmbH for the,commercial ... Poniard is investigating picoplatin, the Company,s lead,product candidate, ... 3 trial in small cell lung cancer, and ...
... Leading CNS experts collaborate with UBC to provide ... To offer clients cutting-edge,thinking in study methodology ... the formation of a European Advisory Board for,Data ... UBC in its,ongoing efforts to improve data quality ...
Cached Medicine Technology:Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin 2Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin 3UBC Forms European Advisory Board to Enhance Data Quality of CNS Trials 2UBC Forms European Advisory Board to Enhance Data Quality of CNS Trials 3
(Date:7/31/2015)... Ind. (PRWEB) , ... August 01, 2015 , ... The ... the Global Advisory Panel on the Future of Nursing (GAPFON) 20-21 July 2015 in ... invited to participate in this meeting. , Dr. Silvia Cassiani, Advisor, Nursing and Allied ...
(Date:7/31/2015)... ... July 31, 2015 , ... Recently touted ... in predictive health analytics , Jvion continues to disrupt the predictive analytic ... software that targets patient and population level illness to drive prevention and better ...
(Date:7/31/2015)... ... July 31, 2015 , ... There’s no better way to enjoy the ... time to cook the next meal, making July the most appropriate to be National ... tips and recipes. , Make the next cookout different than the ones in the ...
(Date:7/31/2015)... , ... July 31, 2015 , ... M3 USA MDLinx.com, ... to launch three new Board Exam Courses. , The additions of Gastroenterology, Pulmonology ... Exam Prep from MDLinx makes preparing for the exam easy and painless. MDLinx ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Well-known for ... now offering wedding cakes with custom designs, making life just a little ... beautifully designed wedding cakes for each customer who orders one. , The bakery provides ...
Breaking Medicine News(10 mins):Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2
... , ANDOVER, Mass., July 30 ... a five county region in northeast Ohio, has gone ... solutions and is systematically rolling it out to more ... clinical workstation solution, which includes SSO, advanced authentication and ...
... , , , DENVER ... report financial results for the second quarter ended June 30, 2009 after ... Company has scheduled a conference call for Thursday, August 6, 2009 at ... Interested parties can access the call by dialing (877) 883-0656 ...
... Philadelphia Eagles are looking for 1,200 blood donors ready ... , PHILADELPHIA, July 30 On Saturday, August 8, 2009, ... the 2nd annual Eagles Training Camp blood drive. , , ... The blood drive is scheduled to run from 6:00 a.m. to 12:00 ...
... ORLANDO, Fla., July 30 The Angelman ... Treatment and Research Institute (ATRI), which will direct the ... serve as a hub for more than 30 organizations, ... for this neuro-genetic disorder. The announcement of the ...
... , , , ... premium provider of new and refurbished ultrasound solutions, reported an 87 percent ... Q2 2008. The growth was supported by the sale of more than ... including the Lung and Asthma Center of Central Washington. , , ...
... , GAITHERSBURG, Md., July 30 GenVec, Inc. (Nasdaq: ... for the second quarter ended June 30, 2009 on Thursday, August ... at 10:00 a.m. EDT on Friday, August 7, 2009 to discuss ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO ) , ...
Cached Medicine News:Health News:Summa Health System Creates Quick Win With Their Caregiver Community By Implementing Sentillion's Clinical Workstation Solution 2Health News:Summa Health System Creates Quick Win With Their Caregiver Community By Implementing Sentillion's Clinical Workstation Solution 3Health News:Eagles to Host 2nd Annual American Red Cross Training Camp Blood Drive 2Health News:Angelman Syndrome Foundation Takes Major Step Toward Furthering Research Efforts 2Health News:Angelman Syndrome Foundation Takes Major Step Toward Furthering Research Efforts 3Health News:MedPro Scores 87 Percent Sales Revenue Increase in Second Quarter 2Health News:GenVec Announces Second Quarter 2009 Results Conference Call 2
Specimen-ID™, a Positive Specimen Identification System, assures the permanent link at the bedside between patient and laboratory specimen to prevent sample identification errors....
wCareMed™ utilizes barcode scanning technology to support medication administration. It is a simple to use point of care application that provides access to patient information on a lightweight,...
... Korchek Technologies CareChek Rx ... barcode technology, Windows CE ... integrated scanners (to perform ... the bedside) and an ...
... conjunction with the AutoPPI barcoded wristband, manages ... a specific patient. The system ensures that ... correct patient and provides printed medication delivery ... keeps a record of the caregiver, location ...
Medicine Products: